{"product_id":"rmd-porters-five-forces-analysis","title":"ResMed Inc. (RMD): 5 FORCES Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Michael Porter Five Forces analysis of ResMed Inc. gives you a detailed, research-based view of supplier power, buyer power, competitive rivalry, substitutes, and new entrants, using recent business facts such as \u003cstrong\u003e$5.15B\u003c\/strong\u003e FY2025 revenue, \u003cstrong\u003e$1.43B\u003c\/strong\u003e Q3 FY2026 revenue, \u003cstrong\u003e62.2%\u003c\/strong\u003e Q3 gross margin, operations in \u003cstrong\u003e140\u003c\/strong\u003e countries, and \u003cstrong\u003e36M\u003c\/strong\u003e AirView enrollments. You'll see how ResMed's scale, margins, R\u0026amp;D spend, digital ecosystem, and regulatory barriers shape its market position and competitive pressure, making it a strong study aid for essays, case studies, presentations, and business research.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Porter's Five Forces: Bargaining power of suppliers\u003c\/h2\u003e\n\u003cp\u003eSupplier power over ResMed appears moderate, not high. Large scale, broad geography, product diversification, and active cost control give ResMed enough buying power to push back on most supplier price increases.\u003c\/p\u003e\n\n\u003cp\u003eResMed's scale matters. Q3 FY2026 revenue was \u003cstrong\u003e$1.43B\u003c\/strong\u003e, FY2025 revenue was \u003cstrong\u003e$5.15B\u003c\/strong\u003e, and Q3 gross margin was \u003cstrong\u003e62.2%\u003c\/strong\u003e. That level of revenue lets ResMed spread procurement costs across a large base, which weakens supplier leverage. A supplier is less able to dictate terms when one customer buys at this scale and still protects margins above 60%.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplier-power signal\u003c\/th\u003e\n\u003cth\u003eResMed data point\u003c\/th\u003e\n\u003cth\u003eWhat it means for supplier power\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.15B\u003c\/strong\u003e FY2025 revenue\u003c\/td\u003e\n\u003ctd\u003eLarge purchasing base improves negotiating power\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent profitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e62.2%\u003c\/strong\u003e Q3 FY2026 gross margin\u003c\/td\u003e\n \u003ctd\u003eInput costs are being controlled rather than dictated by vendors\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic spread\u003c\/td\u003e\n\u003ctd\u003eOperations in \u003cstrong\u003e140 countries\u003c\/strong\u003e and more than \u003cstrong\u003e10K employees\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eLess dependence on any single country, plant, or supplier cluster\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial flexibility\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$554M\u003c\/strong\u003e operating cash flow in Q3 FY2026\u003c\/td\u003e\n \u003ctd\u003eSupports multi-source procurement and timely supplier payments\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eGlobal sourcing also reduces supplier power. ResMed operates in \u003cstrong\u003e140 countries\u003c\/strong\u003e with more than \u003cstrong\u003e10K employees\u003c\/strong\u003e, so its supply chain is not tied to one market or one vendor base. The company had \u003cstrong\u003e$1.32B\u003c\/strong\u003e of foreign currency hedging contracts as of March 31, 2026, mainly for Euro, Australian Dollar, and Singapore Dollar exposure. That tells you ResMed buys, manufactures, or sells across multiple currency zones and actively manages cross-border cost risk. The Greenwood, Indiana distribution center, which opened on February 24, 2026, gives ResMed more control over logistics and delivery timing, which reduces the chance that suppliers can use shipping or service delays as bargaining tools.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge revenue base makes procurement more efficient.\u003c\/li\u003e\n \u003cli\u003eMulti-country operations reduce dependence on any one supplier region.\u003c\/li\u003e\n \u003cli\u003eForeign currency hedging lowers the impact of supplier pricing in local currencies.\u003c\/li\u003e\n \u003cli\u003eLogistics control improves ResMed's ability to set delivery terms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed's procurement exposure is spread across categories, which limits the power of any one supplier group. Revenue mix was \u003cstrong\u003e51%\u003c\/strong\u003e Devices, \u003cstrong\u003e37%\u003c\/strong\u003e Masks and Other, and \u003cstrong\u003e12%\u003c\/strong\u003e Residential Care Software. That mix means ResMed does not rely on only one input class. Suppliers of components, consumables, and software services each face a customer with alternative spending priorities. The company generated \u003cstrong\u003e$457M\u003c\/strong\u003e of operating cash flow in Q1 FY2026 and \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 FY2026, which gives it room to negotiate contracts without needing to accept unfavorable payment or pricing terms.\u003c\/p\u003e\n\n\u003cp\u003eMargin trends also point to manageable supplier pressure. FY2025 gross margin was \u003cstrong\u003e59.2%\u003c\/strong\u003e, then moved to \u003cstrong\u003e61.5%\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e62.3%\u003c\/strong\u003e in Q2 FY2026. Improvement in gross margin means cost of goods sold is not rising faster than revenue. If suppliers had strong pricing power, you would usually expect margin compression instead of expansion. FY2026 gross margin guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e suggests ResMed still expects to absorb input costs without major damage to profitability.\u003c\/p\u003e\n\n\u003cp\u003eResMed's internal innovation capacity is another buffer against supplier leverage. The company spent about \u003cstrong\u003e$400M\u003c\/strong\u003e on R\u0026amp;D in FY2025, equal to roughly \u003cstrong\u003e8%\u003c\/strong\u003e of revenue, and it guided FY2026 R\u0026amp;D at \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e of revenue. That spending helps ResMed redesign products around available materials and component substitutes. In plain English, if one supplier raises prices or faces shortages, ResMed has more room to change specifications than a company with weak engineering investment. The December 8, 2025 FDA clearance for Smart Comfort and the February 11, 2026 U.S. launch of AirTouch F30i show a steady product refresh cycle, which lowers supplier power because product designs do not stay fixed for long.\u003c\/p\u003e\n\n\u003cp\u003eThe company's digital platform scale also weakens supplier dependence. By March 31, 2026, ResMed had \u003cstrong\u003e36M\u003c\/strong\u003e patient enrollments in AirView and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices worldwide. A large installed base creates recurring software and service relationships, which are less exposed to a single hardware supplier's leverage. ResMed can also use the platform to standardize design, monitor product performance, and adjust sourcing decisions faster than a smaller competitor can.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eEffect on supplier power\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct mix\u003c\/td\u003e\n\u003ctd\u003e51% Devices, 37% Masks and Other, 12% Residential Care Software\u003c\/td\u003e\n \u003ctd\u003eDiversifies input needs and reduces reliance on one supplier category\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D intensity\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e$400M\u003c\/strong\u003e in FY2025, or about \u003cstrong\u003e8%\u003c\/strong\u003e of revenue\u003c\/td\u003e\n \u003ctd\u003eSupports redesign and substitution if supplier terms worsen\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational cash flow\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$457M\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 FY2026\u003c\/td\u003e\n \u003ctd\u003eImproves purchasing flexibility and contract discipline\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36M\u003c\/strong\u003e AirView patient enrollments and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices\u003c\/td\u003e\n \u003ctd\u003eCreates platform scale that supports sourcing stability\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCurrency and logistics discipline also matter. The \u003cstrong\u003e$1.32B\u003c\/strong\u003e notional value of foreign currency hedges as of March 31, 2026 shows that ResMed actively manages exposure tied to the Euro, Australian Dollar, and Singapore Dollar. That matters because supplier pricing pressure often shows up through exchange rates, freight costs, and local sourcing terms. By hedging, ResMed reduces the chance that a supplier can force price changes through currency swings. The April 30, 2026 restructuring charge of \u003cstrong\u003e$6M\u003c\/strong\u003e tied to workforce planning suggests management is also willing to adjust costs quickly when conditions change.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHedging weakens currency-based supplier pricing pressure.\u003c\/li\u003e\n \u003cli\u003eDistribution control lowers dependence on supplier-driven delivery schedules.\u003c\/li\u003e\n \u003cli\u003eCost restructuring shows management keeps a tight grip on expenses.\u003c\/li\u003e\n \u003cli\u003eStrong cash flow supports multi-year sourcing contracts on better terms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed's FY2026 outlook reinforces this view. Management guided for \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e gross margin and \u003cstrong\u003e19%\u003c\/strong\u003e to \u003cstrong\u003e20%\u003c\/strong\u003e SG\u0026amp;A as a share of revenue. That combination signals disciplined operations and enough scale to absorb supplier variation without giving away margin. Even after the \u003cstrong\u003e$340M\u003c\/strong\u003e acquisition of Noctrix Health on June 1, 2026, ResMed still has the financial depth to manage supply contracts across a broad platform rather than depend on any single vendor.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Porter's Five Forces: Bargaining power of customers\u003c\/h2\u003e\n\n\u003cp\u003eCustomer bargaining power is \u003cstrong\u003emoderate to low\u003c\/strong\u003e because demand is broad, medically necessary, and tied to a sticky digital and device ecosystem. ResMed serves a large, fragmented base of patients, providers, and payers, so no single buyer can easily pressure pricing across the business.\u003c\/p\u003e\n\n\u003cp\u003eThe scale of unmet need matters. A Lancet Respiratory Medicine study published on October 30, 2025 projected about \u003cstrong\u003e77M\u003c\/strong\u003e people in the U.S. suffer from sleep apnea. That kind of demand base is too wide and too fragmented for customers to act like a concentrated buying block. ResMed's FY2025 revenue of \u003cstrong\u003e$5.15B\u003c\/strong\u003e, along with quarterly revenues of \u003cstrong\u003e$1.3B\u003c\/strong\u003e, \u003cstrong\u003e$1.42B\u003c\/strong\u003e, and \u003cstrong\u003e$1.43B\u003c\/strong\u003e, shows a business selling into a large market rather than relying on a handful of large customers. Q3 FY2026 revenue growth of \u003cstrong\u003e11%\u003c\/strong\u003e year over year and Q1 FY2026 growth of \u003cstrong\u003e9%\u003c\/strong\u003e year over year show buyers were still purchasing even with pricing and reimbursement scrutiny.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eIndicator\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters for customer power\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. sleep apnea need base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e77M\u003c\/strong\u003e projected sufferers\u003c\/td\u003e\n \u003ctd\u003eDemand is broad, so buyers are fragmented and less able to negotiate as one group\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.15B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRevenue comes from a large, diverse customer base rather than a few dominant accounts\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly revenue levels\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.3B\u003c\/strong\u003e, \u003cstrong\u003e$1.42B\u003c\/strong\u003e, \u003cstrong\u003e$1.43B\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eRepeated large quarterly sales suggest steady purchasing across segments\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 FY2026 growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e11%\u003c\/strong\u003e year over year\u003c\/td\u003e\n\u003ctd\u003eDemand held up despite pricing and reimbursement pressure\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY2026 growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9%\u003c\/strong\u003e year over year\u003c\/td\u003e\n\u003ctd\u003eCustomers did not force a sharp slowdown in volumes or pricing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe digital ecosystem also weakens buyer leverage. By March 31, 2026, ResMed's platform had \u003cstrong\u003e36M\u003c\/strong\u003e patient enrollments and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices worldwide. That creates switching friction because a customer is not just buying a machine; they are entering a care system with data, monitoring, and ongoing engagement. The device business represented \u003cstrong\u003e51%\u003c\/strong\u003e of revenue and masks and other products another \u003cstrong\u003e37%\u003c\/strong\u003e, so therapy depends on repeated purchases across hardware and consumables. The December 8, 2025 FDA clearance of Smart Comfort, paired with its early 2026 beta rollout to new myAir users and AirSense 11 devices, makes the product more personalized and harder to replace. The May 19, 2026 partnership with ŌURA also broadens sleep data integration and care access, which raises the value of staying inside ResMed's system.\u003c\/p\u003e\n\n\u003cp\u003eThat ecosystem effect matters in Porter's Five Forces because customer power falls when switching costs rise. A patient or provider moving away from ResMed would need to replace not only the device, but also data continuity, app familiarity, and related consumables. The broader the care pathway, the less likely a buyer is to push hard on price alone.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e36M\u003c\/strong\u003e patient enrollments create a large user base that supports retention.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e34M\u003c\/strong\u003e connected devices make the platform data-rich and harder to leave.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e51%\u003c\/strong\u003e Devices and \u003cstrong\u003e37%\u003c\/strong\u003e Masks and Other means the relationship is recurring, not one-time.\u003c\/li\u003e\n \u003cli\u003eSmart Comfort and myAir personalization increase switching friction.\u003c\/li\u003e\n \u003cli\u003eŌURA integration expands the service layer, making price only one part of the decision.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePricing resilience is another sign that customer bargaining power is limited. ResMed posted GAAP gross margins of \u003cstrong\u003e61.5%\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e62.2%\u003c\/strong\u003e in Q3 FY2026, with non-GAAP gross margin of \u003cstrong\u003e62.3%\u003c\/strong\u003e in Q2 FY2026. FY2026 gross margin guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e indicates management does not expect severe buyer-driven discounting. Non-GAAP EPS reached \u003cstrong\u003e$2.86\u003c\/strong\u003e in Q3 FY2026 and net income was \u003cstrong\u003e$392.6M\u003c\/strong\u003e in Q2 FY2026, while operating cash flow was \u003cstrong\u003e$457M\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 FY2026. When a company can keep margins and cash flow at those levels, customers are not forcing deep concessions.\u003c\/p\u003e\n\n\u003cp\u003eClinical urgency also limits customer power. Sleep apnea treatment is medically necessary, not discretionary, so patients and providers cannot simply delay use the way they might postpone a consumer purchase. ResMed has said GLP-1 weight loss medications are increasing patient engagement and diagnosis rather than reducing CPAP demand, which supports ongoing therapy adoption. Revenue growth of \u003cstrong\u003e10%\u003c\/strong\u003e in FY2025 and \u003cstrong\u003e11%\u003c\/strong\u003e in Q3 FY2026 suggests demand remained durable through several reporting periods. Its presence in \u003cstrong\u003e140\u003c\/strong\u003e countries and workforce of more than \u003cstrong\u003e10K\u003c\/strong\u003e employees also supports continuity for patients and providers who need reliable service, follow-up, and device availability.\u003c\/p\u003e\n\n\u003cp\u003eThe revenue mix reduces buyer pressure because customers interact with more than one product category. Devices accounted for \u003cstrong\u003e51%\u003c\/strong\u003e of revenue, Masks and Other for \u003cstrong\u003e37%\u003c\/strong\u003e, and Residential Care Software for \u003cstrong\u003e12%\u003c\/strong\u003e. That mix means a customer buying one item is often part of a broader treatment pathway that includes software, masks, and replacement products. The February 11, 2026 U.S. launch of AirTouch F30i and the March 31, 2026 launch period for Smart Comfort added more reasons for buyers to stay within the system. The April 30, 2026 quarterly cash dividend of \u003cstrong\u003e$0.60\u003c\/strong\u003e per share and continued buybacks suggest management expects demand to remain steady, which is consistent with limited customer leverage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eForce driver\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eEffect on customer bargaining power\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket fragmentation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e77M\u003c\/strong\u003e projected U.S. sleep apnea sufferers\u003c\/td\u003e\n \u003ctd\u003eLower power because buyers are dispersed across patients, providers, and payers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching costs\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36M\u003c\/strong\u003e enrollments and \u003cstrong\u003e34M\u003c\/strong\u003e connected devices\u003c\/td\u003e\n \u003ctd\u003eLower power because changing systems is inconvenient and data is tied to the platform\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePricing resilience\u003c\/td\u003e\n\u003ctd\u003eGross margin of \u003cstrong\u003e61.5%\u003c\/strong\u003e to \u003cstrong\u003e62.2%\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eLower power because buyers are not forcing major discounting\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemand necessity\u003c\/td\u003e\n\u003ctd\u003eSleep apnea therapy is medically required\u003c\/td\u003e\n \u003ctd\u003eLower power because customers cannot easily walk away from treatment\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct breadth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51%\u003c\/strong\u003e Devices, \u003cstrong\u003e37%\u003c\/strong\u003e Masks and Other, \u003cstrong\u003e12%\u003c\/strong\u003e Software\u003c\/td\u003e\n \u003ctd\u003eLower power because customers buy into a treatment system, not a single item\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCustomer power is not zero, though. Payers and providers can still pressure reimbursement, formularies, and procurement terms, especially in markets where they control access. But ResMed's large unmet demand base, recurring consumables, connected-device ecosystem, and stable margin profile make that pressure only partly effective. In practical terms, customers can influence mix and timing, but they have limited power to force structural price cuts across the business.\u003c\/p\u003e\n\u003ch2\u003eResMed Inc. - Porter's Five Forces: Competitive rivalry\u003c\/h2\u003e\n\u003cp\u003eCompetitive rivalry is high, but it is being shaped more by product innovation, software, and market access than by pure price cutting. ResMed has also benefited from a weaker U.S. competitive field while Philips Respironics remained blocked from selling new sleep therapy devices in the U.S. in January 2026 because of remediation and regulatory limits.\u003c\/p\u003e\n\n\u003cp\u003eThe U.S. market gap matters because ResMed posted \u003cstrong\u003e$1.43B\u003c\/strong\u003e in Q3 FY2026 revenue, up \u003cstrong\u003e11%\u003c\/strong\u003e year over year, while FY2025 revenue reached \u003cstrong\u003e$5.15B\u003c\/strong\u003e. That combination shows ResMed was able to win demand while a major rival was constrained.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRivalry factor\u003c\/td\u003e\n\u003ctd\u003eResMed evidence\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitor restraint\u003c\/td\u003e\n\u003ctd\u003ePhilips Respironics could not sell new sleep therapy devices in the U.S. in January 2026\u003c\/td\u003e\n \u003ctd\u003eReduces near-term pressure in a key market and supports share capture\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue momentum\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2026 revenue of \u003cstrong\u003e$1.43B\u003c\/strong\u003e, up \u003cstrong\u003e11%\u003c\/strong\u003e year over year\u003c\/td\u003e\n \u003ctd\u003eShows ResMed is competing effectively even in a contested category\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003eFY2025 revenue of \u003cstrong\u003e$5.15B\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eScale helps fund R\u0026amp;D, distribution, and marketing\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating strength\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2026 operating cash flow of \u003cstrong\u003e$554M\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eStrong cash generation supports investment without forcing margin sacrifice\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe rivalry is still active because the category is mature and customers can compare sleep therapy brands on comfort, ease of use, data features, and clinician adoption. ResMed's new Greenwood, Indiana distribution center, opened on February 24, 2026, strengthens U.S. fulfillment and improves service levels, which matters when rivals are trying to win accounts through speed and reliability.\u003c\/p\u003e\n\n\u003cp\u003eInnovation is the main battleground. ResMed received FDA clearance for Smart Comfort on December 8, 2025 and began a limited U.S. beta rollout in early 2026. It also launched the AirTouch F30i Comfort full-face CPAP mask in the U.S. on February 11, 2026 after earlier releases in Australia and Canada. The May 19, 2026 partnership with ŌURA adds sleep data integration and patient engagement, which pushes rivalry beyond hardware into connected care.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA clearance and beta rollout show ResMed is competing on new features, not just installed base.\u003c\/li\u003e\n \u003cli\u003eMask launches matter because consumables create repeat purchases and customer stickiness.\u003c\/li\u003e\n \u003cli\u003ePartnering on sleep data broadens the competitive field into digital health and behavior tracking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed's spending pattern supports that view. FY2025 R\u0026amp;D spending was \u003cstrong\u003e$400M\u003c\/strong\u003e, or about \u003cstrong\u003e8%\u003c\/strong\u003e of revenue, while FY2026 guidance is \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e of revenue. That tells you the company is choosing to compete through product development, platform depth, and clinical performance rather than through low pricing alone.\u003c\/p\u003e\n\n\u003cp\u003eMargins also show that rivalry has not turned destructive. FY2025 gross margin was \u003cstrong\u003e59.2%\u003c\/strong\u003e, then rose to \u003cstrong\u003e61.5%\u003c\/strong\u003e in Q1 FY2026, \u003cstrong\u003e62.3%\u003c\/strong\u003e in Q2 FY2026, and \u003cstrong\u003e62.2%\u003c\/strong\u003e in Q3 FY2026. Management's FY2026 gross margin guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e and SG\u0026amp;A guidance of \u003cstrong\u003e19%\u003c\/strong\u003e to \u003cstrong\u003e20%\u003c\/strong\u003e of revenue indicate disciplined competition.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003eSignal for rivalry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHealthy profitability before further gains\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePricing and cost control improved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompetition did not force margin compression\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 FY2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMargin discipline continued\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eProfit figures confirm that rivalry is not eroding earnings. Non-GAAP EPS was \u003cstrong\u003e$2.86\u003c\/strong\u003e in Q3 FY2026, and net income was \u003cstrong\u003e$392.6M\u003c\/strong\u003e in Q2 FY2026. Revenue growth of \u003cstrong\u003e9%\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e11%\u003c\/strong\u003e in both Q2 and Q3 FY2026 shows ResMed is growing while preserving profitability.\u003c\/p\u003e\n\n\u003cp\u003eThe competitive field is broader than devices alone. ResMed has \u003cstrong\u003e36M\u003c\/strong\u003e AirView enrollments and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices, which creates a data and software base that rivals must match or beat. Its revenue mix of \u003cstrong\u003e51%\u003c\/strong\u003e Devices, \u003cstrong\u003e37%\u003c\/strong\u003e Masks and Other, and \u003cstrong\u003e12%\u003c\/strong\u003e Residential Care Software shows that rivalry runs across hardware, consumables, and digital care.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAirView and connected devices raise switching costs for clinicians and patients.\u003c\/li\u003e\n \u003cli\u003eMasks and consumables create recurring revenue and make the competitive fight continuous.\u003c\/li\u003e\n \u003cli\u003eSoftware adds a second layer of rivalry because it links care delivery, tracking, and patient engagement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed's operating model also raises the intensity of competition. The 2030 operating model includes product-led leadership roles such as Chief Product Officer, Chief Marketing Officer, and Chief Revenue Officer. That structure suggests the company wants faster coordination across product design, go-to-market execution, and revenue capture. With more than \u003cstrong\u003e10K\u003c\/strong\u003e employees and operations in \u003cstrong\u003e140\u003c\/strong\u003e countries, ResMed competes on global reach as well as product quality.\u003c\/p\u003e\n\n\u003cp\u003eStrategic acquisition has widened the battleground. The June 1, 2026 acquisition of Noctrix Health for \u003cstrong\u003e$340M\u003c\/strong\u003e shows ResMed is moving into adjacent therapeutic devices beyond core CPAP. That matters because rivalry is no longer limited to one product type; it is expanding into nearby treatment categories where clinical evidence, distribution, and brand trust all matter.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic move\u003c\/td\u003e\n\u003ctd\u003eDate\u003c\/td\u003e\n\u003ctd\u003eRivalry effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmart Comfort FDA clearance\u003c\/td\u003e\n\u003ctd\u003eDecember 8, 2025\u003c\/td\u003e\n\u003ctd\u003eImproves feature competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirTouch F30i Comfort U.S. launch\u003c\/td\u003e\n\u003ctd\u003eFebruary 11, 2026\u003c\/td\u003e\n\u003ctd\u003eSupports consumables and replacement cycles\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eŌURA partnership\u003c\/td\u003e\n\u003ctd\u003eMay 19, 2026\u003c\/td\u003e\n\u003ctd\u003eExtends rivalry into sleep data and engagement\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNoctrix Health acquisition\u003c\/td\u003e\n\u003ctd\u003eJune 1, 2026\u003c\/td\u003e\n\u003ctd\u003eExpands competition into adjacent therapies\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCapital strength helps ResMed sustain rivalry. FY2025 revenue of \u003cstrong\u003e$5.15B\u003c\/strong\u003e, Q3 FY2026 revenue of \u003cstrong\u003e$1.43B\u003c\/strong\u003e, a quarterly dividend of \u003cstrong\u003e$0.60\u003c\/strong\u003e per share on April 30, 2026, and a Q1 FY2026 buyback of \u003cstrong\u003e523K\u003c\/strong\u003e shares for \u003cstrong\u003e$150M\u003c\/strong\u003e show it has resources to keep investing. The stock price of \u003cstrong\u003e$196.04\u003c\/strong\u003e on June 8, 2026 reflects that investors still view the company as competitive, even though the ASX CDI had fallen \u003cstrong\u003e26.7%\u003c\/strong\u003e since January 1, 2025, which signals continuing pressure in the market's view.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDividend payments suggest durable cash generation.\u003c\/li\u003e\n \u003cli\u003eShare repurchases show confidence in cash flow and valuation discipline.\u003c\/li\u003e\n \u003cli\u003eThe share price decline shows that investors still price in competitive risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic use, this force is best framed as intense but controlled rivalry. The strongest drivers are competitor weakness in the U.S., rapid product development, connected-care platforms, and scale advantages in distribution and software. The key analytical point is that ResMed competes in a market where innovation and ecosystem reach matter more than discounting.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Porter's Five Forces: Threat of substitutes\u003c\/h2\u003e\n\u003cp\u003eThe threat of substitutes is moderate for ResMed Inc. It is real because wearables, digital health tools, comfort-focused devices, and weight-loss drugs can pull patients toward other options, but the company's clinical position, installed base, and connected therapy ecosystem make full replacement difficult.\u003c\/p\u003e\n\n\u003cp\u003eWearables are the clearest adjacent substitute category. The May 19, 2026 partnership with ŌURA linked sleep data with care education, which shows that consumer sleep tracking is part of the patient journey, not a separate activity. ResMed already had \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices and \u003cstrong\u003e36M\u003c\/strong\u003e AirView enrollments by March 31, 2026, so the line between consumer tracking and medical therapy is getting thinner. The June 1, 2026 \u003cstrong\u003e$340M\u003c\/strong\u003e acquisition of Noctrix Health, a wearable therapeutic device developer, also signals that non-CPAP wearables are relevant either as substitutes or complements. The fact that \u003cstrong\u003e12%\u003c\/strong\u003e of revenue came from Residential Care Software shows that digital and lifestyle tools are now part of the therapy stack.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSubstitute category\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWearables\u003c\/td\u003e\n\u003ctd\u003eŌURA partnership on May 19, 2026; Noctrix Health acquisition on June 1, 2026 for \u003cstrong\u003e$340M\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eShows consumer and therapeutic wearables can compete with or complement CPAP therapy\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeight-loss drugs\u003c\/td\u003e\n\u003ctd\u003eGLP-1 analysis showed higher engagement and diagnosis rather than lower CPAP demand\u003c\/td\u003e\n \u003ctd\u003ePharmacological approaches may change treatment behavior, but they have not replaced therapy demand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComfort-oriented device alternatives\u003c\/td\u003e\n\u003ctd\u003eSmart Comfort approved December 8, 2025; AirTouch F30i launched February 11, 2026\u003c\/td\u003e\n \u003ctd\u003eImproved comfort reduces the appeal of switching away from ResMed's own products\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sleep tools\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36M\u003c\/strong\u003e AirView enrollments; \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices\u003c\/td\u003e\n \u003ctd\u003eCreates a broad treatment pathway that makes replacement harder\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWeight-loss drugs do not currently replace therapy. ResMed said its analysis of GLP-1 weight-loss medications showed they increase patient engagement and diagnosis rather than reduce overall CPAP demand. That matters because the company still posted \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year revenue growth in Q3 FY2026 and \u003cstrong\u003e10%\u003c\/strong\u003e growth in FY2025. The U.S. sleep apnea estimate of \u003cstrong\u003e77M\u003c\/strong\u003e people means the underlying condition remains large even as weight management options expand. Q3 revenue of \u003cstrong\u003e$1.43B\u003c\/strong\u003e and operating cash flow of \u003cstrong\u003e$554M\u003c\/strong\u003e show demand stayed strong after GLP-1 adoption accelerated. So the substitute risk from pharmacological approaches is present, but current data point to complementarity rather than replacement.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGLP-1 drugs may reduce weight, but they do not remove the need to diagnose and manage sleep apnea.\u003c\/li\u003e\n \u003cli\u003eResMed's revenue kept growing at \u003cstrong\u003e11%\u003c\/strong\u003e in Q3 FY2026, which suggests substitution pressure has not broken demand.\u003c\/li\u003e\n \u003cli\u003eA market of \u003cstrong\u003e77M\u003c\/strong\u003e U.S. sleep apnea sufferers is large enough to support both drug-based and device-based care paths.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$554M\u003c\/strong\u003e in operating cash flow shows the core therapy model remained healthy during the GLP-1 expansion period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eComfort features blunt switching. ResMed's FDA-cleared Smart Comfort system, approved on December 8, 2025, provides personalized therapy settings that can reduce the appeal of alternative treatments. The early 2026 beta rollout to new myAir app users paired with AirSense 11 devices shows the company is using software to protect adherence, which means patients are less likely to abandon therapy for a substitute. The February 11, 2026 U.S. launch of AirTouch F30i also addresses comfort, one of the main reasons patients look for substitutes. Gross margin held at \u003cstrong\u003e61.5%\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e62.2%\u003c\/strong\u003e in Q3 FY2026, which suggests these enhancements are being monetized effectively rather than eroding economics.\u003c\/p\u003e\n\n\u003cp\u003eDigital ecosystem effects reduce replacement risk. ResMed had \u003cstrong\u003e36M\u003c\/strong\u003e patient enrollments in AirView and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices worldwide as of March 31, 2026. That creates a data-rich treatment loop that helps patients, providers, and the company stay connected over time. With \u003cstrong\u003e51%\u003c\/strong\u003e of revenue from Devices, \u003cstrong\u003e37%\u003c\/strong\u003e from Masks and Other, and \u003cstrong\u003e12%\u003c\/strong\u003e from Residential Care Software, customers are embedded in a multi-product pathway. FY2025 revenue of \u003cstrong\u003e$5.15B\u003c\/strong\u003e and Q3 FY2026 revenue of \u003cstrong\u003e$1.43B\u003c\/strong\u003e show that this ecosystem is already commercially large. The \u003cstrong\u003e140\u003c\/strong\u003e-country footprint and more than \u003cstrong\u003e10K\u003c\/strong\u003e employees make the platform hard to displace with a single substitute product.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices create ongoing data capture and follow-up.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e36M\u003c\/strong\u003e AirView enrollments deepen provider involvement.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e51%\u003c\/strong\u003e of revenue from Devices shows the core product remains central.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e37%\u003c\/strong\u003e from Masks and Other and \u003cstrong\u003e12%\u003c\/strong\u003e from Residential Care Software show that switching would require replacing an entire system, not just one device.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eClinical need limits substitution. The October 2025 estimate of \u003cstrong\u003e77M\u003c\/strong\u003e U.S. sleep apnea sufferers shows treatment demand is driven by diagnosis and medical necessity, not just product preference. FY2026 gross margin guidance of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e and R\u0026amp;D guidance of \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e indicate ResMed expects sustained demand for its core therapies and continued investment in product improvement. Q1 FY2026 revenue of \u003cstrong\u003e$1.3B\u003c\/strong\u003e, Q2 revenue of \u003cstrong\u003e$1.42B\u003c\/strong\u003e, and Q3 revenue of \u003cstrong\u003e$1.43B\u003c\/strong\u003e show the business has not been derailed by alternative approaches. The continued dividend of \u003cstrong\u003e$0.60\u003c\/strong\u003e per share and share repurchases also reflect confidence in recurring therapy use, which keeps the substitute threat real but contained by the chronic nature of sleep apnea care.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003cth\u003eSignal for substitute threat\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDemand remained stable despite rising interest in alternative approaches\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.42B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrowth continued rather than slowing sharply\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 FY2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.43B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubstitute pressure did not materially weaken revenue momentum\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.15B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLarge revenue base supports ongoing investment in retention and innovation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eResMed Inc. - Porter's Five Forces: Threat of new entrants\u003c\/h2\u003e\n\n\u003cp\u003eThe threat of new entrants is low to moderate. ResMed Inc. faces high regulatory, clinical, capital, and distribution barriers, so a new company would need time, money, approvals, and scale before it could compete seriously.\u003c\/p\u003e\n\n\u003cp\u003eRegulation is one of the biggest barriers. Medical devices need clear evidence, formal approvals, and strong quality systems before they can reach patients. ResMed's FDA clearance for Smart Comfort on December 8, 2025 shows how long product validation can take. Its 2024 Form 10-K also pointed to ongoing intellectual property protections, which make it harder for rivals to copy product features. A newly listed Form SD on May 26, 2026 for conflict minerals compliance shows how much supply chain reporting and oversight is required in medical hardware. With more than \u003cstrong\u003e10,000\u003c\/strong\u003e employees across \u003cstrong\u003e140\u003c\/strong\u003e countries, ResMed also has operating depth that a new entrant would struggle to match.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eBarrier\u003c\/td\u003e\n\u003ctd\u003eResMed Inc. evidence\u003c\/td\u003e\n\u003ctd\u003eWhy it matters for new entrants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory approval\u003c\/td\u003e\n\u003ctd\u003eFDA clearance for Smart Comfort on December 8, 2025\u003c\/td\u003e\n \u003ctd\u003eNew products need evidence, testing, and review before launch\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual property\u003c\/td\u003e\n\u003ctd\u003eOngoing protections noted in the 2024 Form 10-K\u003c\/td\u003e\n \u003ctd\u003eLimits copying and raises legal risk for imitators\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply chain compliance\u003c\/td\u003e\n\u003ctd\u003eForm SD filed on May 26, 2026 for conflict minerals compliance\u003c\/td\u003e\n \u003ctd\u003eEntrants need strong sourcing controls and reporting systems\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal operating scale\u003c\/td\u003e\n\u003ctd\u003eMore than 10,000 employees in 140 countries\u003c\/td\u003e\n \u003ctd\u003eEntrants must build logistics, service, and compliance capacity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eInstalled base also blocks fast entry. By March 31, 2026, ResMed had \u003cstrong\u003e36M\u003c\/strong\u003e AirView patient enrollments and \u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices worldwide. That is not just a product base; it is a service ecosystem tied to patients, providers, and payers. FY2025 revenue was \u003cstrong\u003e$5.15B\u003c\/strong\u003e, and quarterly revenue stayed above \u003cstrong\u003e$1.3B\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e$1.42B\u003c\/strong\u003e in Q2 FY2026. The revenue mix of \u003cstrong\u003e51%\u003c\/strong\u003e Devices, \u003cstrong\u003e37%\u003c\/strong\u003e Masks and Other, and \u003cstrong\u003e12%\u003c\/strong\u003e Residential Care Software creates cross-sell opportunities and switching friction. A new entrant would need more than a device. It would need a connected platform, reimbursement access, and trust across the care pathway.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e36M\u003c\/strong\u003e AirView patient enrollments create a large data and service base.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e34M\u003c\/strong\u003e cloud-connected devices increase switching costs for providers and patients.\u003c\/li\u003e\n \u003cli\u003eThe \u003cstrong\u003e51% \/ 37% \/ 12%\u003c\/strong\u003e revenue mix supports cross-selling across hardware, consumables, and software.\u003c\/li\u003e\n \u003cli\u003eRecurring relationships matter because sleep therapy products are not one-time purchases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInnovation spend raises the bar further. ResMed spent about \u003cstrong\u003e$400M\u003c\/strong\u003e on R\u0026amp;D in FY2025, equal to roughly \u003cstrong\u003e8%\u003c\/strong\u003e of revenue, and guided FY2026 R\u0026amp;D at \u003cstrong\u003e6%\u003c\/strong\u003e to \u003cstrong\u003e7%\u003c\/strong\u003e of revenue. The launch of AirTouch F30i on February 11, 2026 and the December 2025 Smart Comfort clearance show a steady product pipeline. Q3 FY2026 revenue growth of \u003cstrong\u003e11%\u003c\/strong\u003e and gross margin of \u003cstrong\u003e62.2%\u003c\/strong\u003e give the company room to keep investing. The 2030 operating model, with product-led leadership across product, marketing, and revenue, also supports faster execution. A new entrant would need similar spending and technical talent just to stay close.\u003c\/p\u003e\n\n\u003cp\u003eCapital and scale make entry expensive. The June 1, 2026 acquisition of Noctrix Health for \u003cstrong\u003e$340M\u003c\/strong\u003e shows that ResMed can buy capability instead of building it slowly. In Q1 FY2026, it repurchased \u003cstrong\u003e523,000\u003c\/strong\u003e shares for \u003cstrong\u003e$150M\u003c\/strong\u003e and paid a quarterly dividend of \u003cstrong\u003e$0.60\u003c\/strong\u003e per share, which signals financial strength. Operating cash flow of \u003cstrong\u003e$457M\u003c\/strong\u003e in Q1 FY2026 and \u003cstrong\u003e$554M\u003c\/strong\u003e in Q3 FY2026 gives it room to fund growth and protect market position. The Greenwood, Indiana distribution center and operations in \u003cstrong\u003e140\u003c\/strong\u003e countries add another layer of logistics complexity. A newcomer would need heavy upfront capital before proving clinical acceptance.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh cash generation supports continued investment in product development and distribution.\u003c\/li\u003e\n \u003cli\u003eShare repurchases and dividends show financial flexibility.\u003c\/li\u003e\n \u003cli\u003eGlobal logistics and manufacturing scale are hard to copy quickly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe market is attractive, which can draw challengers. The October 2025 estimate of \u003cstrong\u003e77M\u003c\/strong\u003e U.S. sleep apnea sufferers points to a large addressable market, and FY2025 revenue of \u003cstrong\u003e$5.15B\u003c\/strong\u003e shows that the category is profitable. ResMed's stock price of \u003cstrong\u003e$196.04\u003c\/strong\u003e on June 8, 2026 and FY2026 gross margin outlook of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e can also attract new competitors. But the same numbers show the scale barrier. Strong demand does not make entry easy when approval, reimbursement, clinical trust, software integration, and global supply chains all matter.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket signal\u003c\/td\u003e\n\u003ctd\u003eData point\u003c\/td\u003e\n\u003ctd\u003eEffect on entry threat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e77M U.S. sleep apnea sufferers\u003c\/td\u003e\n\u003ctd\u003eAttracts challengers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProfit pool\u003c\/td\u003e\n\u003ctd\u003eFY2025 revenue of $5.15B\u003c\/td\u003e\n\u003ctd\u003eAttracts investment and competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin profile\u003c\/td\u003e\n\u003ctd\u003eFY2026 gross margin outlook of 62% to 63%\u003c\/td\u003e\n \u003ctd\u003eSignals room for profitable competition, but only at scale\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth rate\u003c\/td\u003e\n\u003ctd\u003e11% revenue growth in Q3 FY2026 and 10% growth in FY2025\u003c\/td\u003e\n \u003ctd\u003eShows demand, but also raises the bar for rivals\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor Porter's Five Forces analysis, the key point is that ResMed Inc. operates in a market where entry is possible but not easy. New companies face approval hurdles, IP barriers, connected-device infrastructure, large R\u0026amp;D needs, and major capital requirements before they can build a credible alternative.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44600339038357,"sku":"rmd-porters-five-forces-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rmd-porters-five-forces-analysis.png?v=1740210901","url":"https:\/\/dcf-model.com\/products\/rmd-porters-five-forces-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}